Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells.

Li X, Kuang J, Shen Y, Majer MM, Nelson CC, Parsawar K, Heichman KA, Kuwada SK.

J Biol Chem. 2012 Jun 29;287(27):23171-83. doi: 10.1074/jbc.M112.379412. Epub 2012 May 14.

2.

The Histone Variant MacroH2A1.2 Is Necessary for the Activation of Muscle Enhancers and Recruitment of the Transcription Factor Pbx1.

Dell'Orso S, Wang AH, Shih HY, Saso K, Berghella L, Gutierrez-Cruz G, Ladurner AG, O'Shea JJ, Sartorelli V, Zare H.

Cell Rep. 2016 Feb 9;14(5):1156-1168. doi: 10.1016/j.celrep.2015.12.103. Epub 2016 Jan 28.

3.

Messenger RNAs encoding mouse histone macroH2A1 isoforms are expressed at similar levels in male and female cells and result from alternative splicing.

Rasmussen TP, Huang T, Mastrangelo MA, Loring J, Panning B, Jaenisch R.

Nucleic Acids Res. 1999 Sep 15;27(18):3685-9.

4.

Weak but uniform enrichment of the histone variant macroH2A1 along the inactive X chromosome.

Mietton F, Sengupta AK, Molla A, Picchi G, Barral S, Heliot L, Grange T, Wutz A, Dimitrov S.

Mol Cell Biol. 2009 Jan;29(1):150-6. doi: 10.1128/MCB.00997-08. Epub 2008 Oct 20.

5.

Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.

Yang JW, Kim MR, Kim HG, Kim SK, Jeong HG, Kang KW.

Arch Pharm Res. 2008 Mar;31(3):350-6. doi: 10.1007/s12272-001-1163-z. Epub 2008 Apr 13.

PMID:
18409049
6.

The histone variant mH2A1.1 interferes with transcription by down-regulating PARP-1 enzymatic activity.

Ouararhni K, Hadj-Slimane R, Ait-Si-Ali S, Robin P, Mietton F, Harel-Bellan A, Dimitrov S, Hamiche A.

Genes Dev. 2006 Dec 1;20(23):3324-36.

7.

Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells.

Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R.

J Biol Chem. 2005 Jul 1;280(26):24428-34. Epub 2005 May 3.

8.

ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.

Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D.

Mol Cancer Res. 2009 Apr;7(4):592-600. doi: 10.1158/1541-7786.MCR-08-0316.

9.

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.

Oncogene. 1998 Oct 29;17(17):2235-49.

10.

Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.

Nolens G, Pignon JC, Koopmansch B, Elmoualij B, Zorzi W, De Pauw E, Winkler R.

Breast Cancer Res. 2009;11(6):R83. doi: 10.1186/bcr2450. Epub 2009 Nov 11.

11.

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ.

Oncogene. 1997 Jul 31;15(5):537-47.

12.

Towards sustained silencing of HER2/neu in cancer by epigenetic editing.

Falahi F, Huisman C, Kazemier HG, van der Vlies P, Kok K, Hospers GA, Rots MG.

Mol Cancer Res. 2013 Sep;11(9):1029-39. doi: 10.1158/1541-7786.MCR-12-0567. Epub 2013 Jun 27.

15.

Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer.

Sporn JC, Jung B.

Am J Pathol. 2012 Jun;180(6):2516-26. doi: 10.1016/j.ajpath.2012.02.027. Epub 2012 Apr 27.

16.
17.
18.

Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.

Delacroix L, Begon D, Chatel G, Jackers P, Winkler R.

DNA Cell Biol. 2005 Sep;24(9):582-94.

PMID:
16153159

Supplemental Content

Support Center